Safety of tenofovir use during pregnancy: Early growth outcomes in HIV-exposed uninfected infants

AIDS

Volumn 26, Issue 9, 2012, Pages 1151-1159

  Siberry, George K ^a   Williams, Paige L ^b,d   Mendez, Hermann ^c   Seage, George R ^b   Jacobson, Denise L ^d   Hazra, Rohan ^a   Rich, Kenneth C ^e   Griner, Raymond ^d   Tassiopoulos, Katherine ^b   Kacanek, Deborah ^d   Mofenson, Lynne M ^a   Miller, Tracie ^e   Dimeglio, Linda A ^f   Watts, D Heather ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral drugs; infant growth; perinatal HIV exposure; pregnancy; tenofovir disoproxil fumarate

Indexed keywords

TENOFOVIR DISOPROXIL;

ARTICLE; BIRTH WEIGHT; CHILD; CHILD GROWTH; COHORT ANALYSIS; FEMALE; HEAD CIRCUMFERENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREGNANCY; PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SMALL FOR DATE INFANT;

ADENINE; ANTI-HIV AGENTS; BODY SIZE; CHILD DEVELOPMENT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; MALE; PHOSPHONIC ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84861526377     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328352d135     Document Type: Article

References (28)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; pp. 1-166. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed 2 November 2011]
2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. September 14, 2011; pp. 1-207. Available at http://aidsinfo.nih.gov/ContentFiles/Perinatal GL.pdf [Accessed 2 November 2011]
3. Tarantal A, Castillo A, Ekert J, Bischofberger N, Martin R. Fetal and maternal outcome after administration of tenofovir to gravid Rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29:207-220.
4. Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl.]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48:1469-1487.
5. Van Rompay K, Durand-Gasselin L, Brignolo L, Ray A, Abel K, Cihlar T, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics, biological and virological effects. Antimicrob Agents Chemother 2008; 52:3144-3160.
6. Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM. Tenofovir disproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med 2009; 10:397-406.
7. Hirt D, Urien S, Ekouévi DK, Rey E, Arrivé E, Blanche S, et al., ANRS 12109. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther 2009; 85:182-189.
8. Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann Pharmacother 2008; 42:1581-1585.
9. Tassiopoulos K, Read JS, Brogly S, Rich K, Lester B, Spector SA, et al. Substance use in HIV-infected women during pregnancy: self-report versus meconium analysis. AIDS Behav 2010; 14:1269-1278.
10. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al. CDC growth charts: United States. Adv Data 2000; 314:1-27.
11. Fenton TF, Sauve RS. Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart. Eur J Clin Nutr 2007; 61:1380-1385.
12. Fenton TR. A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format. BMC Pediatr 2003; 3:13.
13. Pacheco SE, McIntosh K, Lu M, Mofenson LM, Diaz C, Foca M, et al., Women and Infants Transmission Study. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the women and infants transmission study. J Infect Dis 2006; 194:1089-1097.
14. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-1089.
15. Landreau-Mascaro A, Barret B, Mayaux MJ, Tardieu M, Blanche S. Risk of early febrile seizures with perinatal exposure to nucleoside analogues. Lancet 2002; 359:583-584.
16. Benhammou V, Warszawski J, Bellec S, Doz F, André N, Lacour B, et al., ANRS-Enquête Périnatale Française. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. AIDS 2008; 22:2165-2177.
17. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S, Enquête Périnatale Française Study Group. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17:2053-2061.
18. Poirier MC, Olivero OA, Walker DM, Walker VE. Perinatal genotoxicity and carcinogenicity of antiretroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004; 199:151-161.
19. Maagaard A, Kvale D. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother 2009; 64:901-909.
20. Biesecker G, Karimi S, Desjardins J, Meyer D, Abbott B, Bendele R, et al. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys, and woodchucks. Antiviral Res 2003; 58:217-225.
21. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al., ASSERT Study Group. Comparison of changes in bone density and turnover with abacavirlamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-972.
22. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224 s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-1801.
23. Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005; 116:e846-e854.
24. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:e711-e718.
25. Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, van Widenfelt E, et al. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana. J Acquir Immune Defic Syndr 2011; 56:131-138.
26. Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, Faye A, et al., ANRS French Perinatal Cohort. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 2009; 23:1235-1243.
27. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-1870.
28. Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG, Pediatric Spectrum of HIV Disease Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989-2004. Pediatrics 2007; 119:e900-e906.